TAMARA ARBOLEDA: Open Payments
NPI 1750915112 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,241 in 84 payments from 32 companies in 2025. Trend: 2023 $810 · 2024 $472 · 2025 $2,241
Food & beverage: $2,163Education: $78
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 10 | $274 |
| AstraZeneca Pharmaceuticals LP | 7 | $176 |
| SOBI, INC | 5 | $158 |
| Janssen Biotech, Inc. | 6 | $144 |
| GlaxoSmithKline, LLC. | 5 | $116 |
| Novartis Pharmaceuticals Corporation | 4 | $110 |
| Eisai Inc. | 4 | $109 |
| Syndax Pharmaceuticals, Inc. | 3 | $90 |
| ABBVIE INC. | 3 | $83 |
| Geron Corporation | 3 | $81 |
Products named: KEYTRUDA, Vonjo, Lenvima, CALQUENCE, Fabhalta, RYBREVANT, OJJAARA, RYTELO.
Industry payments across TX — which companies pay providers there.
